Skip to content

The prophylactic effect of theophylline on vancomycin-induced nephrotoxicity

Investigating the effect of theophylline on vancomycin-induced nephrotoxicity in children aged one month to 18 years with severe infection compared to vancomycin alone.

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20220326054351N1
Enrollment
34
Registered
2022-08-30
Start date
2022-08-23
Completion date
Unknown
Last updated
2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

nephrotoxicity.

Interventions

Intervention 1: Intervention group:Patients are treated with vancomycin and theophylline. Vancomycin is prescribed at a dose of 15 mg/kg every eight hours from the first day of hospitalization. The du

Sponsors

Sabzevar University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
1 Months to 18 Years

Inclusion criteria

Inclusion criteria: Patients with systemic infection treated with vancomycin Patients one month to 18 years Complete the informed consent form

Exclusion criteria

Exclusion criteria: Patients who are discharged from the hospital before three days. Patients with unpredictable complications. Patients with drug side effects.

Design outcomes

Primary

MeasureTime frame
The percentage of people treated with vancomycin who develop microalbuminuria. Timepoint: Measurement of microalbuminuria at the beginning of the study and 72 hours after starting treatment with vancomycin. Method of measurement: Measurement of microalbuminuria in urine sample.The range is 30-300 mg per 24 hours.;The percentage of people treated with vancomycin who experience an increase in urea and creatinineCommunity Verified icon. Timepoint: Measurement of urea and creatinine at the beginning of the study and 72 hours after starting vancomycin treatment. Method of measurement: Measurement of urea and creatinine in serum samples.Depending on the patients age, urea 20-30 mg/dL and creatinine 0.4-1 mg/dL.

Secondary

MeasureTime frame
Patient weight change. Timepoint: before treatment & after three days from the start of treatment. Method of measurement: Measuring the patient's weight in kilograms with a digital scale.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAghil Keykhosravi

Sabzevar University of Medical Sciences

drakeykhosravi@yahoo.com+98 51 4401 1600

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026